HC Wainwright Issues Pessimistic Forecast for FibroBiologics (NASDAQ:FBLG) Stock Price

FibroBiologics (NASDAQ:FBLG – Get Free Report) had its target price cut by investment analysts at HC Wainwright from $6.00 to $4.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price target would suggest a potential upside of 381.93% from the company’s previous close.

A number of other research analysts also recently commented on FBLG. Weiss Ratings raised FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, September 4th. Wall Street Zen raised shares of FibroBiologics to a “hold” rating in a report on Saturday, October 10th. Finally, Deutsche Bank lowered shares of FibroBiologics to an “underperform” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $72.00.

Get Our Latest Report on FBLG

FibroBiologics Price Performance

Shares of NASDAQ:FBLG opened at $0.83 on Friday. FibroBiologics has a 1 year low of $0.62 and a 1 year high of $9.60. The business’s 50 day simple moving average is $1.11 and its 200 day simple moving average is $2.02.

FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.25. On average, equities analysts predict that FibroBiologics will post -3.00 EPS for the current year.

Institutional Investors Weigh In On FibroBiologics

A hedge fund recently bought a new position in FibroBiologics stock. IFP Advisors Inc bought a new stake in FibroBiologics Inc. (NASDAQ:FBLG – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 27,000 shares of the company’s stock, valued at approximately $35,000. IFP Advisors Inc owned 0.41% of FibroBiologics as of its most recent SEC filing.

FibroBiologics Company Profile

(Get Free Report)

FibroBiologics is a clinical-stage biotechnology company developing cell-based therapies for chronic diseases. Its research centers on fibroblasts, cells found in connective tissue that can support tissue repair and other biological processes. The company is developing potential therapies for conditions including multiple sclerosis, degenerative disc disease, wound healing and diabetes. Its programs are investigational, and the company’s approach includes exploring fibroblast cells and related technologies as treatments.

Read More

Analyst Recommendations for FibroBiologics (NASDAQ:FBLG)

Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.